...
首页> 外文期刊>Journal of Molecular Structure >Structural investigation of isatin-based benzenesulfonamides as carbonic anhydrase isoform IX inhibitors endowed with anticancer activity using molecular modeling approaches
【24h】

Structural investigation of isatin-based benzenesulfonamides as carbonic anhydrase isoform IX inhibitors endowed with anticancer activity using molecular modeling approaches

机译:基于Isatin的苯磺酰磺酰胺作为碳酸酐酶同种型IX抑制剂使用分子建模方法赋予抗癌活性的结构研究

获取原文
获取原文并翻译 | 示例
           

摘要

Carbonic anhydrase IX (CA IX) is a trans membrane protein that highly expressed in hypoxia tumor cells. Selective inhibition of CA IX isoenzyme by small molecule CA inhibitors such as sulfonamide derivatives has blocked tumor growth in multiple cancer models and CA IX is a promising target for cancer therapy. In the present research, molecular modeling investigations, such as CoMFA, CoMFA-RF, CoMSIA and HQSAR, molecular docking molecular and dynamics (MD) simulations were carried out on a series of isatin-based benzenesulfonamide derivatives as CA IX inhibitors, which was split randomly into training (n = 43) and test set (n = 15). The statistical qualities of generated models were justified by internal and external validation, i.e., cross-validated correlation coefficient (q(2)), non-cross validated correlation coefficient (r(ncv)(2)) and predicted correlation coefficient (r(pred)(2)), respectively. The CoMFA (q(2), 0.712; r(ncv)(2), 0.848; r(pred)(2), 0.908), CoMFA-RF (q(2), 0.719; r(ncv)(2), 0.890; r(pred)(2), 0.926), CoMSIA (q(2), 0.717; r(ncv)(2), 0.841; r(pred)(2), 0.915) and HQSAR models (q(2), 0.782; r(ncv)(2), 0.849; r(pred)(2), 0.935) for training and test set of CA IX inhibition yielded significant statistical findings. Several external parameters, such as, Q(F1)(2), Q(F2)(2), Q(F3)(2) and CCC were 0.907, 0.901, 0.716 and 0.954 (CoMFA); 0.926, 0.907, 0.715 and 0.959 (CoMFA-RF); 0.914, 0.909, 0.738 and 0.952 (CoMSIA) and 0.937, 0.933, 0.808 and 0.962 (HQSAR), respectively. Therefore, these QSAR models were excellent, robust and had better predictive capability. Contour maps of all models were generated and validated by molecular docking and molecular dynamics simulation studies, that the steric, hydrophobic and hydrogen bonding fields are crucial in these models for improving the binding affinity and determine of structure- activity relationship. The docking results showed that Gln92, His94, His96, His119 and Thr200 were important residues in the active site of CA IX. The primary sulfonamide group of these derivatives as scaffold and the isatin tail scaffold groups as hydrophobic and electrostatic parts are essential for improving CA IX protein inhibitory activity. Based on these results, five new CA IX inhibitors were designed by the molecular models which showed good potential activity and reasonably good ADMET profiles and could selectively inhibit hCA IX. These theoretical results are possibly beneficial to rational design of new potent CA IX inhibitors with enhanced activity to treat cancer. (C) 2020 Elsevier B.V. All rights reserved.
机译:碳酸酐酶IX(CA IX)是一种跨膜蛋白,在缺氧肿瘤细胞中高度表达。小分子钙抑制剂(如磺酰胺衍生物)选择性抑制CA-IX同功酶已在多种癌症模型中阻断肿瘤生长,CA-IX是一个很有希望的癌症治疗靶点。在本研究中,对一系列作为CA-IX抑制剂的基于靛红的苯磺酰胺衍生物进行了分子建模研究,如CoMFA、CoMFA RF、CoMSIA和HQSAR、分子对接分子动力学(MD)模拟,并将其随机分为训练组(n=43)和测试组(n=15)。通过内部和外部验证,即交叉验证相关系数(q(2))、非交叉验证相关系数(r(ncv)(2))和预测相关系数(r(pred)(2)),验证了生成模型的统计质量。CoMFA(q(2),0.712;r(ncv)(2),0.848;r(pred)(2),0.908),CoMFA-RF(q(2),0.719;r(ncv)(2),0.890;r(pred)(2),0.926),CoMSIA(q(2),0.717;r(ncv)(2),0.841;r(pred)(2),0.915)和HQSAR模型(q(2),0.782;r(ncv)(2),0.849;对于CA-IX抑制的训练和测试集,r(pred)(2),0.935)产生了显著的统计结果。几个外部参数,如Q(F1)(2)、Q(F2)(2)、Q(F3)(2)和CCC分别为0.907、0.901、0.716和0.954(CoMFA);0.926、0.907、0.715和0.959(CoMFA RF);分别为0.914,0.909,0.738和0.952(CoMSIA)和0.937,0.933,0.808和0.962(HQSAR)。因此,这些QSAR模型具有良好的鲁棒性和更好的预测能力。通过分子对接和分子动力学模拟研究,生成并验证了所有模型的等高线图,空间、疏水和氢键场在这些模型中对于提高结合亲和力和确定结构-活性关系至关重要。对接结果表明,Gln92、His94、His96、His119和Thr200是CA-IX活性部位的重要残基。这些衍生物的一级磺酰胺基作为支架,isatin尾支架基作为疏水和静电部分对于提高CA-IX蛋白抑制活性至关重要。基于这些结果,通过分子模型设计了五种新的CA-IX抑制剂,它们表现出良好的潜在活性和相当好的ADMET谱,并且可以选择性地抑制hCA-IX。这些理论结果可能有助于合理设计具有增强癌症治疗活性的新型有效CA-IX抑制剂。(C) 2020爱思唯尔B.V.版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号